Description: Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company's products include OPDIVO intravenous infusions for treating malignant tumor; KYPROLIS, a proteasome inhibitor for intravenous injection; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Glactiv and FORXIGA tablets for type II diabetes; Kinedak tablets to treat diabetic peripheral neuropathy; Recalbon tablets to treat osteoporosis; ORENCIA injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease treatment; Onoact injections for treating tachyarrhythmia; Staybla tablets for overactive bladder; Opalmon tablets to treat peripheral circulatory disorder; Onon capsules and dry syrups for treating bronchial asthma and allergic rhinitis; and Foipan tablets for treating chronic pancreatitis and postoperative reflux esophagitis. It is also developing products for gastric, colorectal, small and non-small cell lung, head and neck, urothelial, esophageal, ovarian, biliary tract, hematologic cancers; and hodgkin lymphoma, hepatocellular carcinoma, glioblastoma, malignant pleural mesothelioma, multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, solid tumor, central nervous system lymphoma, primary testicular lymphoma, virus positive/negative solid carcinoma, chronic myeloid leukemia, cancer anorexia/cachexia, melanoma, pheochromocytoma, acute leukemia, juvenile idiopathic arthritis, lupus nephritis, untreated rheumatoid arthritis, primary sjögren syndrome, polymyositis/dermatomyositis, chronic heart failure, tachyarrhythmia, ventricular arrhythmia, sepsis, hepatitis C, parkinson's disease, overactive bladder, osteoarthritis, sjögren syndrome, and underactive bladder. Ono Pharmaceutical Co., Ltd. has collaboration agreements with Eisai Co., Ltd. and Schrödinger Inc., Fate Therapeutics, Inc., and Merus N.V. The company was founded in 1717 and is headquartered in Osaka, Japan.
Home Page: www.ono-pharma.com
8-2, Kyutaromachi 1-chome
Osaka,
541-8564
Japan
Phone:
81 6 6263 5670
Officers
| Name | Title |
|---|---|
| Mr. Gyo Sagara | CEO & Chairman of the Board |
| Mr. Toichi Takino Ph.D. | President, COO & Representative Director |
| Mr. Masaki Ito | Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., and Corp. Tax |
| Takehiro Yamada | Corporate Officer & Head of Risk and Compliance Management Department |
| Satoshi Takahagi | Corporate Executive Off. and Exe. Dir. of Sales, Marketing & Oncology Business Division |
| Masayuki Tanigawa | Corporate Officer & Head of Business Strategy Headquarters |
| Mr. Toshihiro Tsujinaka | Ex. EO, Exe. Dir. of Sus. Promotion Corp. Strategy, Planning & HR Divi. and Representative Dir. |
| Hiromu Habashita Ph.D. | Corporate Officer & Deputy Executive Director, Discovery & Research |
| Shinji Takai M.D., Ph.D. | Corporate Officer & Head of Medical Affairs |
| Akira Takada | Corporate Executive Officer, Executive Director, CMC & Production, Production Technology Management |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 13.8696 |
|---|---|
| Trailing PE: | 9.3985 |
| Price-to-Book MRQ: | 1.0082 |
| Price-to-Sales TTM: | 0.011 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 4258 |